{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056994","form_type":"8-K","ticker":null,"cik":"0001850079","company_name":"Telesis Bio Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.814410+00:00","generated_at":"2026-06-02T07:04:05.923944+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Telesis Bio Q1 revenue $3.4M down 46% YoY; net loss $8.6M improves from $11.1M","bullets":["Revenue $3.4M vs $6.3M YoY; product revenue fell $1.7M and collaboration revenue $1.0M.","Net loss $8.6M ($5.52 EPS) vs $11.1M ($6.75 EPS) YoY; operating expenses cut 31% to $10.0M.","Cash, equivalents and investments $15.7M at March 31, 2024; long-term notes payable $5.2M.","Strategic focus on Gibson SOLA and BioXp mRNA; 40% of new instrument buyers cite mRNA workflow.","Pfizer collaboration progressing; no forward-looking guidance provided."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056994","json":"https://secwatch.observer/filing/0000950170-24-056994.json","markdown":"https://secwatch.observer/filing/0000950170-24-056994.md","text":"https://secwatch.observer/filing/0000950170-24-056994.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024056994/0000950170-24-056994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024056994/tbio-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:04:05.923944+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b7850fb362217b64ff958fad5081c7e4a1d3719b","claim":"Telesis Bio Inc. reported the quarter ended March 31, 2024 results: revenue $3.4 million, net income $8.6 million, EPS $5.52.","evidence_excerpt":"strategy, is reduced 31% from the first quarter of the prior year. Summary of First Quarter 2024 Financial Results Revenue for the three months ended March 31, 2024 was $3.4 million compared to $6.3 million for the three months ended March 31, 2023. The decrease of $2.9 million was attributable to a decrease in product revenue of $1.7 million, a decrease in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024056994/0000950170-24-056994-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$3.4 million"},{"label":"Net income","value":"$8.6 million"},{"label":"EPS","value":"$5.52"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}